From Vaccine Supply to Securing Hospital Beds... KDCA Overhauls Infectious Disease Response System
Announcement of the Plan for Advancing Infectious Disease Crisis Management Systems
Response Differentiated by "Limited Transmission" and "Pandemic" Types
Integration of Infectious Disease Beds and Strengthening Vaccine Development Capacity
The Korea Disease Control and Prevention Agency (KDCA) is overhauling its infectious disease response system. The agency plans to preemptively establish infrastructure for hospital beds, vaccines, treatments, and clinical trials in order to prepare for the next pandemic. On June 10, the KDCA announced the "Plan for Advancing the Infectious Disease Crisis Management System," which details these measures.
Accordingly, the KDCA will classify infectious disease crisis types into "limited transmission," which can be eradicated domestically, and "pandemic," which requires long-term coexistence. For overseas infectious diseases not legally designated in Korea but with potential for domestic entry, the risk will be assessed to select diseases that require preparation, and proactive management systems will be established.
The KDCA will also establish an infectious disease crisis social response manual and create new subcommittees for disease control and social response, with participation from experts across all sectors of society. The agency is also reviewing measures to secure continuous and stable funding dedicated to preparedness and rapid response during a crisis.
Additionally, the agency will integrate and reorganize nationally designated hospital beds and emergency treatment beds into "national infectious disease beds," and designate the medical institutions operating these beds as regional infectious disease hospitals.
The plan also calls for building collaborative networks with domestic and international pharmaceutical companies and global vaccine organizations to strengthen vaccine supply capacity in times of crisis. A joint public-private Vaccine Rapid Introduction Subcommittee will be formed to review the safety and efficacy of vaccines before introduction. A "Government-wide Vaccine Introduction Council," with participation from relevant ministries, will also be established.
A new "tentatively named Infectious Disease Clinical Research and Analysis Center" will be established to oversee public clinical trials. The agency will intensively support organizations with core mRNA technology, from preclinical stages through phase 3 clinical trials, aiming to localize COVID-19 mRNA vaccine production by 2028. A vaccine prototype library for priority pathogens will also be built and stockpiled during normal times, enabling rapid development within 100 to 200 days during a crisis.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The agency will also pursue the development of the Korean Pandemic Preparedness Engine (K-AI PPX), an AI-based R&D platform that provides integrated support for ultra-rapid antigen design and the entire vaccine development cycle. To secure key technology sovereignty and ensure integrated response, the government will formulate the "Fourth National Infectious Disease Crisis Response Technology Development Strategy" in collaboration with all relevant ministries.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.